CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
This site is intended for U.S. animal healthcare professionals
The first monoclonal antibody (mAB) therapy for chronic canine allergic and atopic dermatitis1
The first monoclonal (mAB) antibody therapy for chronic canine atopic dermatitis1
CYTOPOINT® mimics the dog’s natural immune function; it targets IL-31, which is involved in the cycle of itch and inflammation2
A closer look at the MOA of CYTOPOINT
How CYTOPOINT works
CYTOPOINT is a monoclonal antibody (mAb)* treatment for dogs that specifically targets and neutralizes canine IL-31,† an important cytokine‡ involved in sending the itch signal to the brain in chronic atopic dermatitis2
Because it is highly targeted to a specific cytokine involved in canine atopic dermatitis, CYTOPOINT has minimal impact on normal immune functions3
CYTOPOINT is eliminated via normal protein degradation pathways in the same way as naturally occurring antibodies§; metabolism does not involve the liver or kidneys
Monoclonal antibody (mAb): a single, homogenous antibody preparation derived from a single lineage of B cells. Monoclonal antibody therapy is designed to mimic a normal immune function by recognizing and binding to one single segment, or epitope, on a particular target antigen.4,5
Interleukin 31 (IL-31): a cytokine that triggers the process of sending itch signals to the brain.2
Cytokine: a protein that signals other cells by binding to receptors on those cells.6
mAbs are catabolized within cells into amino acids and peptides. They are not metabolized in the liver or kidneys, converted into reactive or toxic metabolites, or excreted in urine. Thus, they are highly unlikely to induce liver or kidney toxicity.
Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
References: 1. Data on file, Press Release, August 2015, Zoetis Inc. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 3. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 4. Olivry T, Bainbridge G. Clinician's Brief. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. March 2015. https://www.zoetisus.com/conditions/dogs/itchcycle/downloads/resources/publications/zoetiscn_mar_fnl.pdf. Accessed October 21, 2017. 5. Greenfield EA. Generating monoclonal antibodies. In: Greenfield EA, ed. Antibodies: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2014:201-221. 6. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014; 37(4):317-324. doi:10.1111/jvp.12101.
This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.